Genomic Analyses Identifies Molecular Subtypes of Pancreatic Cancer
By LabMedica International staff writers Posted on 07 Mar 2016 |
Image: Histopathology of two clusters of precancerous cells (lower half of image), which arose in pancreatic cells expressing the pancreas/duodenum homeobox protein 1 and the cancer gene KRAS (Photo courtesy of Sharon Friedlander).
Most patients with pancreatic cancer only live a few months after diagnosis and the disease is set to become the second most common cancer in westernized countries in the next 10 years.
A detailed analysis of DNA disruption, gene expression and molecular pathways in hundreds of tumors, has led to the conclusion that pancreatic cancer is not one but four separate diseases, each with a different genetic trigger and requiring a different treatment.
An international team led by Australian scientists at the University of Melbourne (Australia) have studied the genetics of pancreatic cancer, revealing it is actually four separate neoplasms, each with different genetic triggers and survival rates, paving the way for more accurate diagnoses and treatments. The team identified 32 genes from 10 genetic pathways that are consistently mutated in pancreatic tumors, but further analysis of gene activity revealed four distinct subtypes of tumors.
The team analyzed the genomes of 456 pancreatic tumors to identify the underlying genetic and molecular processes that go wrong inside cells when normal pancreatic tissue changes into aggressive cancer. Using an approach called "integrated genomic analysis," the team brought together techniques that analyze not only genetic code, but also variations in structure and gene activity. This is the first time such an analysis has revealed so much about the genetic damage that leads to pancreatic cancer.
Expression analysis defined four subtypes: (1) squamous; (2) pancreatic progenitor; (3) immunogenic; and (4) aberrantly differentiated endocrine exocrine (ADEX) that correlate with histopathological characteristics. They found some types of pancreatic cancer have mutations typically seen in colon cancer and leukemia, for which treatments are already available. Immunogenic tumors contained upregulated immune networks including pathways involved in acquired immune suppression.
Sean M. Grimond, PhD, a professor and coauthor of the study, said, “We identified 32 genes from 10 genetic pathways that are consistently mutated in pancreatic tumors, but further analysis of gene activity revealed four distinct subtypes of tumors. This study demonstrates that pancreatic cancer is better considered as four separate diseases, with different survival rates, treatments and underlying genetics. Knowing which subtype a patient has would allow a doctor to provide a more accurate prognosis and treatment recommendations.” The study was published on February 24, 2016, in the journal Nature.
Related Links:
University of Melbourne
A detailed analysis of DNA disruption, gene expression and molecular pathways in hundreds of tumors, has led to the conclusion that pancreatic cancer is not one but four separate diseases, each with a different genetic trigger and requiring a different treatment.
An international team led by Australian scientists at the University of Melbourne (Australia) have studied the genetics of pancreatic cancer, revealing it is actually four separate neoplasms, each with different genetic triggers and survival rates, paving the way for more accurate diagnoses and treatments. The team identified 32 genes from 10 genetic pathways that are consistently mutated in pancreatic tumors, but further analysis of gene activity revealed four distinct subtypes of tumors.
The team analyzed the genomes of 456 pancreatic tumors to identify the underlying genetic and molecular processes that go wrong inside cells when normal pancreatic tissue changes into aggressive cancer. Using an approach called "integrated genomic analysis," the team brought together techniques that analyze not only genetic code, but also variations in structure and gene activity. This is the first time such an analysis has revealed so much about the genetic damage that leads to pancreatic cancer.
Expression analysis defined four subtypes: (1) squamous; (2) pancreatic progenitor; (3) immunogenic; and (4) aberrantly differentiated endocrine exocrine (ADEX) that correlate with histopathological characteristics. They found some types of pancreatic cancer have mutations typically seen in colon cancer and leukemia, for which treatments are already available. Immunogenic tumors contained upregulated immune networks including pathways involved in acquired immune suppression.
Sean M. Grimond, PhD, a professor and coauthor of the study, said, “We identified 32 genes from 10 genetic pathways that are consistently mutated in pancreatic tumors, but further analysis of gene activity revealed four distinct subtypes of tumors. This study demonstrates that pancreatic cancer is better considered as four separate diseases, with different survival rates, treatments and underlying genetics. Knowing which subtype a patient has would allow a doctor to provide a more accurate prognosis and treatment recommendations.” The study was published on February 24, 2016, in the journal Nature.
Related Links:
University of Melbourne
Latest Molecular Diagnostics News
- Blood Proteins Could Warn of Cancer Seven Years before Diagnosis
- New DNA Origami Technique to Advance Disease Diagnosis
- Ultrasound-Aided Blood Testing Detects Cancer Biomarkers from Cells
- New Respiratory Syndromic Testing Panel Provides Fast and Accurate Results
- New Synthetic Biomarker Technology Differentiates Between Prior Zika and Dengue Infections
- Novel Biomarkers to Improve Diagnosis of Renal Cell Carcinoma Subtypes
- RNA-Powered Molecular Test to Help Combat Early-Age Onset Colorectal Cancer
- Advanced Blood Test to Spot Alzheimer's Before Progression to Dementia
- Multi-Omic Noninvasive Urine-Based DNA Test to Improve Bladder Cancer Detection
- First of Its Kind NGS Assay for Precise Detection of BCR::ABL1 Fusion Gene to Enable Personalized Leukemia Treatment
- Urine Test to Revolutionize Lyme Disease Testing
- Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease
- New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk
- Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis
- Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans